cis-Dichloroplatinum(II) complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-ones: Synthesis and cytotoxicity in human cancer cell lines in vitro

In vitro DNA and BSA-binding, cell imaging and anticancer activity against human carcinoma cell lines of mixed ligand copper(II) complexes

“…This effect was also observed for cisplatin. These results reveal that the IC 50 value for complex (1) against HT-29 is very smaller than reported IC 50 value for the cisplatin drug and, consequently, the HT-29 cell line is more sensitive to this complex than cisplatin [54]. The IC 50 values obtained for these complexes are larger than other Cu(II) complex (except IC 50 value for complex (1) against HT-29) [55].…”

Synthesis, characterization, X-ray crystal structure, electrochemical evaluation and anti-cancer studies of a mixed ligand Cu(II) complex of (E)-N′-((2-hydroxynaphthalen-1-yl)methylene)acetohydrazide

“…IC 50 value for the complex against MCF-7 cell line was calculated to be 2.4 μM which was significantly smaller than that reported for the well-known anticancer drug, cis-platin. 39,40 IC 50 value for HL was found to be 17.4 μM. So, the [Cu(L)(Phen)] synthesized here can be proposed as an efficient anti-cancer agent alternative for cis-platin.…”

A mononuclear Cu(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: Synthesis, crystal structure, DNA- and BSA-binding, molecular modeling, and anticancer activity against MCF-7, A-549, and HT-29 cell lines

“…Consequently, all three human carcinoma cell lines, MCF-7, A-549, and HT-29, are more sensitive to this complex than cisplatin [75,76].…”